Kevin Horgan
CIK 1510614 · View on SEC EDGAR ↗
First SEC filing: Nov. 6, 2013 · Latest: Nov. 6, 2013
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| April 22, 2014 | FBIOP | S | 47,566 | $1.89 | $89,900 | 0 Direct | -100.00% | Disposed | 870.9% (price as of 2026-08-21) |
| April 17, 2014 | FBIOP | S | 101 | $1.85 | $187 | 0 Direct | -100.00% | Disposed | 891.9% (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 25, 2019 | MCRB | STOCK OPTION (RIGHT TO BUY) | Common Stock (30,000) | $6.01 | Jan. 24, 2029 | 30,000 | Acquired |
| Oct. 23, 2018 | MCRB | Stock Option (right to buy) | Common Stock (225,000) | $6.58 | Oct. 22, 2028 | 225,000 | Acquired |
| April 22, 2014 | FBIOP | Options to purchase Common Stock | Common Stock (47,566) | $1.71 | Nov. 5, 2023 | 47,566 | Disposed |
| April 17, 2014 | FBIOP | Options to purchase Common Stock | Common Stock (101) | $1.71 | Nov. 5, 2023 | 101 | Disposed |
| Nov. 5, 2013 | FBIOP | Options to purchase Common Stock | Common Stock (200,000) | $1.71 | Nov. 5, 2023 | 200,000 | Acquired |
| Sept. 25, 2013 | SNGX | Stock Option (Right to Buy) [F1] | Common Stock (85,000) | $0.68 | Dec. 4, 2022 | 85,000 | Acquired |
| Dec. 1, 2011 | SNGX | Stock Option (Right to Buy) [F1] | Common Stock (1,200,000) | $0.03 | Nov. 30, 2021 | 1,200,000 | Acquired |
| Jan. 31, 2011 | SNGX | Stock Option (Right to Buy) [F1] | Common Stock (1,250,000) | $0.17 | Jan. 30, 2021 | 1,250,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Nov. 6, 2013 | FBIOP | No securities beneficially owned | 0 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
FBIOP
M.D. Former Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2014 | — | — | — | — | — | — | $340,000 | $340,000 |
| 2013 | $54,406 | — | — | $288,000 | — | — | — | $342,406 |
| 2012 | — | — | — | — | — | — | — | — |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.